Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03863626
Other study ID # N-166-2018
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 31, 2019
Est. completion date December 2021

Study information

Verified date January 2021
Source Cairo University
Contact Ahmad Samir, MD
Phone 00201002647275
Email ahmad.samir@kasralainy.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. Evaluate efficacy and safety of continuous infusion of IV Frusemide compared to IV shots in acute decompensated heart failure ADHF 2. Evaluate superiority of time-adjusted metolazone to morning frusemide IV shots compared to irrespective administration (at random times) to overcome diuretic resistance


Description:

After admission for acute decompensated heart failure and ensuring eligibility to participate in the study, accepting patients will be randomized by a pre-prepared tables into 2 equal groups (A = shots, B = infusion): - Patients randomized to the Frusemide IV shots arm (group A) will be started on 80 mg frusemide daily (or at the least equal to their prior oral dose if was on >80 mg oral frusemide or equivalent doses of other loop diuretics). Dose will be allowed to be modified by judging the urine output in every 3 hours. Patients randomized to continuous IV infusion arm (group B) will receive 84 mg Frusemide daily (40 mg bolus followed by 2 mg/ hour starting infusion rate). An extra bolus and/or modification of the infusion rate will be allowed after judging the urine output in 3 hours. The same regimen would be continued for at least 72 hours, or more than 72 hours if needed till switching to oral diuretics. In patients who develop diuretic resistance defined as failure to achieve therapeutically desired urine output despite maximal doses of loop diuretics will be managed by adding thiazide type diuretic "Metolazone" to the regimen to achieve sequential nephron blockade. Metolazone (2.5 - 10 mg /day) addition will be allowed in both arms when deemed indicated, however, in the IV shots arm, there will be further 1:1 randomization for either giving metolazone timed 60 minutes before the morning IV frusemide shot (group A.T) or metolazone at random time irrespective of the frusemide dose timing (group A.R). Variables that will be assessed in the patients to evaluate the prespecified end-points are:- - Urine output in L/day as absolute volume and indexed volume to body weight. - Weight loss in Kg as absolute number and in percentage of initial body weight. - Diuretic efficiency defined as amount of urine output per 40mg frusemide. - Impact on hemodynamics assessed by change in mean arterial pressure, inducing hypotension (systolic below 80 mmHg or requiring denovo vasopressors), or new clinical signs of hypoperfusion. - Cumulative dose of IV frusemide per 72 hours. - Improvement of NYHA class as judged by the treating physician. - Number of days to introduction/restoring dose of betablockade therapy. - Number of days to switch to oral diuretics as judged by the treating physician. - Duration of ICU stay and of hospital stay. - Change in serum creatinine (either rising or falling) in absolute value and percentage from baseline creatinine, as well as in eGFR equated by Cockcroft-Gold equation. - Occurrence of worsening renal function (WRF) as defined by rise of serum creatinine by ≥ 0.3 mg/dl. - Occurrence of 50% and or 100% rise in serum creatinine or indication to renal replacement therapy. - Change in serum potassium as absolute value from baseline or below target range (between 4.0 - 5.0 mEq/dl). Serum potassium level will be routinely checked twice daily in the first 72 hours then once daily or every 48 hours as seen necessary. - Inducing denovo hypomagnesemia (below 1.8mg/dl) or hyponatremia (below 135 mEq/dl) - Rehospitalization within 30 days for new heart failure decompensation, and hospitalization for any cause. VI. Study outcomes 1. Primary outcome - Time (in hours) to improvement of NYHA class when frusemide is given as shots compared to infusion. - Urine output (in ml/kg/h) per 40 mg of frusemide given as shots vs continuous infusion. 2. Secondary outcome(s) - Assessment of additive benefit of addition of metolazone to frusemide in ADHF. - Evaluating superiority of timely adjusted metolazone compared to given at random in overcoming resistance to IV frusemide (IV shots arm).


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age more than 18 years. - Chronic heart failure prior diagnosis, based on signs and or symptoms of heart failure, presenting with acute decompensation as judged by the physician to require hospitalization for IV diuretics Exclusion Criteria: - Refusal to participate in the study. - Allergy to IV frusemide. - Severe renal impairment defined as eGFR<30ml/m. - Cardiogenic shock or hemodynamic instability judged by the treating physician to be unsuitable to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Frusemide IV shots
giving frusemide by IV shots And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)
Frusemide IV infusion
giving frusemide by continuous IV infusion And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade

Locations

Country Name City State
Egypt Faculty of Medicine, Cairo University Hospitals Cairo

Sponsors (2)

Lead Sponsor Collaborator
Cairo University Kasr El Aini Hospital

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015 Jun 14;36(23):1437-44. doi: 10.1093/eurheartj/ehv010. Epub 2015 Apr 2. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to improvement of NYHA class Time (in hours) to improvement of NYHA class within 5 days
Primary Diuretic efficiency Urine output (in ml/kg/h) per 40 mg of frusemide given as shots vs continuous infusion. 24 hours
Secondary effectiveness of sequential nephron block Assessing improvement of diuresis by adding of metolazone to frusemide in ADHF.patients who had developed diuretic resistance. within 5 days of adding metolazone
Secondary Evaluating superiority of timely adjusted metolazone compared to given at random in overcoming resistance to IV frusemide (only in IV shots arm) Evaluating superiority of timely adjusted metolazone given 60 minutes prior to IV frusemide compared to when given at random in overcoming diuretic resistance (only in IV shots arm) within 5 days of adding metolazone
See also
  Status Clinical Trial Phase
Completed NCT04049045 - Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Recruiting NCT02898181 - Low Level Tragus Stimulation in Acute Decompensated Heart Failure N/A
Completed NCT02823626 - High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure
Completed NCT02248831 - Evaluation of Cardiopulmonary Diseases by Ultrasound N/A
Completed NCT02196038 - A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients N/A
Completed NCT00693745 - Neutrophil Gelatinase-Associated Lipcalin (NGAL) Evaluation Along With B-Type Natriuretic Peptide in Acutely Decompensated HF N/A
Not yet recruiting NCT04391231 - HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial Phase 4
Recruiting NCT05206422 - DORAYA-HF Early Feasibility Study N/A
Recruiting NCT01960218 - Gas Exchange for Predicting Hospital Heart Failure Readmissions N/A
Terminated NCT00904488 - Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure Phase 4
Terminated NCT02620384 - Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study. Phase 3
Completed NCT04318093 - Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure Phase 2
Recruiting NCT06161649 - Mobile Education System to Improve Disease Knowledge, Self-efficacy and Quality of Life in Patients With Heart Failure N/A
Completed NCT02289508 - Role of USCOM in Adult Patients With Heart Failure N/A
Terminated NCT01457053 - Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics N/A
Completed NCT04877652 - DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Completed NCT03146754 - A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE) N/A
Terminated NCT05346653 - The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure Phase 4